JOHN DAVID HANSEN Insider Trading $MBVX MABVAX THERAPEUTICS HOLDINGS, INC.

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for JOHN DAVID HANSEN.

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of JOHN DAVID HANSEN. JOHN DAVID HANSEN is V.P. of Corporate Development in AVANIR PHARMACEUTICALS, INC. ($AVNR) and President and CEO in MABVAX THERAPEUTICS HOLDINGS, INC. ($MBVX).

JOHN DAVID HANSEN in MABVAX THERAPEUTICS HOLDINGS, INC.

Trading Symbol: MBVX
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN DAVID HANSEN: President and CEO
Holdings: 536,730 shares
Current Value: $1,594,088
Latest Transaction: Feb 23 2018
$MBVX Market Capitalization: $18.01M
$MBVX Previous Close: $2.97

Last 4 weeks trend: HOLD
Last 3 months trend: HOLD

Latest Insider Trading Transactions of JOHN DAVID HANSEN in MABVAX THERAPEUTICS HOLDINGS, INC.

1 Week2 Weeks1 Month3 Months6 Months1 Year2 Years
No. of Purchases0000000
Value of Purchases ($)0000000
No. of Sales0000000
Value of Sales ($)0000000

Sentiment: All, AVNR, MBVX

Page:   1

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
Feb 23 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA2.04290,000591,600290,000
Feb 23 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA2.04290,000591,600290,000
Jan 18 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS0.9259,26354,522536,730596 K to 536.7 K (-9.94 %)
Jan 16 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseM0.00727,21000
Jan 16 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS0.9618,58217,839595,993614.6 K to 596 K (-3.02 %)
Jan 16 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS0.9864,01562,735614,575678.6 K to 614.6 K (-9.43 %)
Jan 16 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS0.96110,093105,689678,590788.7 K to 678.6 K (-13.96 %)
Jan 16 2018MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOBuyM0.00727,2100788,68361.5 K to 788.7 K (+1,182.97 %)
Oct 04 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA0.00551,1560551,156
Sep 18 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA0.00176,0540176,054
Aug 02 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseS6.293,11919,6190
Aug 02 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseS5.553,11917,3100
Aug 02 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOBuyP0.004,842070,60165.8 K to 70.6 K (+7.36 %)
Aug 02 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOBuyP1.754,2867,50165,75961.5 K to 65.8 K (+6.97 %)
May 23 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA2.00500,0001,000,000500,000
Apr 14 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS2.0010,21620,43361,47371.7 K to 61.5 K (-14.25 %)
Apr 11 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS2.0025050071,68971.9 K to 71.7 K (-0.35 %)
Apr 11 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS2.005601,12071,93972.5 K to 71.9 K (-0.77 %)
Apr 11 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS2.016661,33572,49973.2 K to 72.5 K (-0.91 %)
Apr 06 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS2.151,5013,22373,16574.7 K to 73.2 K (-2.01 %)
Apr 06 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS2.152,4505,27174,66677.1 K to 74.7 K (-3.18 %)
Apr 06 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOSellS2.251,1002,47577,11678.2 K to 77.1 K (-1.41 %)
Apr 04 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseM0.0040,687040,687
Apr 04 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOBuyM0.0040,687078,21637.5 K to 78.2 K (+108.41 %)
Feb 08 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA2.99250,000747,500250,000
Jan 03 2017MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA3.3863,400214,29263,400
Aug 30 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA5.0063,400317,00063,400
Aug 19 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseP6.293,11919,6193,119
Aug 19 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseP5.553,11917,3103,119
Aug 19 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOBuyP0.003,119037,52934.4 K to 37.5 K (+9.06 %)
Apr 05 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseM0.00301,1840602,166
Apr 05 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOPayment of ExerciseF0.00113,1480254,634367.8 K to 254.6 K (-30.76 %)
Apr 05 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOBuyM0.00301,0840367,78266.7 K to 367.8 K (+451.41 %)
Feb 18 2016MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPRESIDENT AND CEOOption ExerciseA0.49500,000245,000500,000
Apr 03 2015MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPresident and CEOOption ExerciseA0.00903,2500903,250
Apr 03 2015MBVXMABVAX THERAPEUTIC ...HANSEN JOHN DAVIDPresident and CEOOption ExerciseA2.30903,2502,077,475903,250

Page:   1

Contact us | Follow us on Twitter